Condition

EGFR clinical trials and research

• 9Clinical trials
• 26Countries

Newest EGFR clinical trials

All recruiting trials (9)

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• Sequential pemetrexed + carboplatin followed by befotertinib for EGFR‑mutant NSCLC after resistance to third‑generation EGFR inhibitors

  This treatment plan will see if giving pemetrexed plus carboplatin followed by the oral drug befotertinib helps people with EGFR‑mutant non‑small cell lung cancer who have stopped responding to third‑generation EGFR inhibitors.

  Recruiting at 2 sites Phase 2 Betta Pharmaceuticals Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07181499

• Zipalertinib vs placebo after surgery for uncommon EGFR-mutant NSCLC

  This study tests whether zipalertinib can help people with early-stage, surgically removed NSCLC that has uncommon EGFR mutations-by comparing it to placebo.

  Recruiting at 108 sites Phase 3 Taiho Oncology, Inc. · Anchorage, Alaska and 252 other locations · NCT07128199

• Trilaciclib given before sacituzumab tirumotecan to protect bone marrow in EGFR-mutated advanced NSCLC

  This trial will test whether giving trilaciclib before sacituzumab tirumotecan helps protect the blood and reduce blood-related side effects in people with advanced EGFR‑mutated non-small cell lung cancer who have stopped responding to EGFR-TKI therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06992739

• Evaluating VIR-5525 and its combination with Pembrolizumab for advanced solid tumors

  This study is testing a new treatment called VIR-5525, alone and with another drug called pembrolizumab, to see if it can help people with advanced solid tumors that have a specific protein called EGFR.

  Recruiting at 4 sites Phase 1 Vir Biotechnology, Inc. · Scottsdale, Arizona and 3 other locations · NCT06960395

• Comparing firmonertinib to chemotherapy for advanced lung cancer with specific mutations

  This study is testing whether a new drug called firmonertinib can work better than standard chemotherapy for people with advanced lung cancer who have specific genetic mutations.

  Recruiting at 2 sites Phase 3 Allist Pharmaceuticals, Inc. · Beijing, Beijing Municipality and 1 other locations · NCT06956001

• Combining Befotertinib with Bevacizumab or Chemotherapy for Lung Cancer Treatment

  This study is testing if a new lung cancer treatment combining befotertinib with either bevacizumab or chemotherapy can help patients with early-stage cancer that has an EGFR mutation feel better before surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT06755684

Related topics

Quick answers

How many EGFR clinical trials are recruiting right now?

9, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in China (5 trials), United States (3 trials), France (2 trials), Australia (2 trials), South Korea (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →